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• CSII initiation significantly improved HbA1c levels after 6 months with sustainable effects lasting up to 10 years 
 
• Patients more likely to benefit the most from CSII are those with prior poor glycaemic control  
 
• Switching pump models at end of initial warranty did not significantly change glycaemic control irrespective of HbA1c category on switch 
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• Continuous subcutaneous insulin infusion therapy (CSII) has been 
proven to be superior over intensified insulin therapy using multiple 
daily injections 1 
 
• Studies are showing conflicting data on long-term follow-up of CSII 
therapy, from sustained benefit over 6 years 2 to loss of it after 3 
years 3 
 
• Our aim was to assess both the short-term and long-term impact of 
CSII on HbA1c changes in Type 1 diabetes 
 
• Retrospective, observational study of 517 adults with Type 1 diabe-
tes starting on CSII between 2002 and 2017 
 
• Exclusion criteria were unavailability of baseline HbA1c and at least 
one follow-up HbA1c level - 474 eligible patients in total 
 
• Comparisons were made between subgroups classified by baseline 
HbA1c level:  -  ≥69 mmol/mol 
         -  58.5-69 mmol/mol 
         -  <58.5 mmol/mol 
Pump change did not alter HbA1c levels further CSII initiation improved poorly controlled DM  
Figure 3:  Effect of pump change on median HbA1c levels by HbA1c category 
    (Wilcoxon signed-rank test, ns - not significant (p>0.05)) 
Figure 2:  Effect of CSII initiation on median HbA1c levels by HbA1c category 
    (Wilcoxon signed-rank test, *** p<0.001, ** p<0.01, * p<0.05, ns - not significant, p>0.05) 
Figure 1:  Effect of CSII initiation on median overall HbA1c levels. Red points show raw data for each individual 
    (Wilcoxon signed-rank test, *** p<0.001, ns - not significant, p>0.05) 
CSII provides sustainable improvement of HbA1c levels 
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